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Abstract The aim of this study
was to test the efficacy of short-
term transcutaneous electrical
nerve stimulation (TENS) treat-
ment in chronic pain with respect
to pain intensity and patients’
satisfaction with treatment results.
We therefore performed
a randomised controlled trial
comparing TENS and sham TENS.
Patients, researchers and therapists
were blinded for treatment
allocation. One hundred and
sixty-three patients with chronic
pain referred to the Pain Centre
entered the study. Conventional
TENS and sham TENS were
applied in the segments of pain,
for a period of ten days. Outcome
measures were pain intensity
(visual analogue scale) and
patients’ satisfaction with treat-
ment result (yes or no). The pro-
portions of patients satisfied with
treatment result differed signifi-
cantly for TENS compared to
sham TENS (58 and 42.7%
respectively, x2=3.8, p=0.05).
However, no differences in pain
intensity were found for patients
treated with TENS or sham TENS.
Only for patients satisfied with
treatment results pain intensity
gradually decrease equally both
for TENS and sham TENS with
repeated treatment application.
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Introduction
Transcutaneous electrical nerve stimulation (TENS) is an
easy to use, non-invasive intervention that alleviates pain.
Although TENS treatment has been used since the early
1970s, results of treatment of patients with chronic pain
are still inconclusive [1, 2]. These unclear results may be
due to the fact that TENS treatment was applied intermit-
tently for only short periods with stimulation time of less
than 10 h/week [2], in different poorly defined modalities
[1]. This treatment is of shorter duration and stimulation
time than recommended treatments [3]. Furthermore, the
use of different pain outcome measures gave contrary
results, e.g., in patients with chronic low back pain,
Moore and Shurman [4] found a significant difference in
pain relief for TENS treatment as measured by a pain
relief scale, but documented no pain reduction using a
visual analogue scale (VAS), both compared with placebo,
after two days of treatment. So patients did experience
relief after this short treatment period, although this could
not be retrieved by diminished VAS scores.
In exploring the effect of TENS treatment in chronic
pain, measuring pain intensity by VAS [1] and calculat-
ing group means is very common to evaluate differences
between TENS and sham TENS, assuming continuous
and normally distributed data. However, situations might
arise in which a particular treatment application pro-
duces a substantial benefit in a moderate proportion of
patients, but no change in others. In this case, it is impor-
tant to know that in animal research high-frequency
TENS is effective in reducing hyperalgesia in the inflam-
matory pain model in rats [5], but not in a rat model of
peripheral nerve ligation [6]. Also, for placebo response
it is assumed that patients either do respond or do not
respond [7]. For bimodal data, when there is little or no
difference in group mean values, it is still possible that
there might be a statistically significant difference in
proportions of patients achieving a clinically important
benefit, as proposed by Farrar et al. [8]. A problem may
arise when trying to define “a clinically important
improvement” for the result of TENS treatment when
TENS is applied for short periods. A 50% change in pain
intensity has been used to evaluate TENS treatment
effect in patients with osteoarthritis; Smith et al. [9]
found 50% or more relief in pain intensity in 67% and
27% of the patients treated with TENS and sham TENS
respectively; treatment was applied 8 times for 20 min
over a period of 4 weeks. However, Marchand et al. [10]
found in patients with low back pain that TENS signifi-
cantly decreased intensity ratings in a cumulative man-
ner over repeated treatment sessions. So for shorter peri-
ods of TENS treatment, less pain reduction may be
expected than for longer treatment periods.
Willingness to continue TENS is more commonly used
to evaluate treatment effect in daily practice and is
assumed to reflect the result of a balance between effort
and therapeutic result [11]. After 3 months of TENS treat-
ment, Eriksson et al. [12] found 50% pain relief or more
in 72% of the patients with chronic pain, who continued to
use TENS after an initial short trial period. Therefore,
willingness to continue TENS seems to be a preferable
and clinically relevant outcome measure to evaluate short-
term effects of TENS.
The aim of this study is to test the efficacy of short-
term TENS treatment with respect to these outcome mea-
sures. Our primary research question is: is there a differ-
ence in the proportions of patients with chronic pain, sat-
isfied with the initial treatment result and willing to con-
tinue TENS or sham TENS, after a short treatment period?
Our secondary questions are: is there a difference in relief
in pain intensity between patients treated with TENS or
sham TENS, and do patients treated with TENS or sham
TENS and who are satisfied with the initial treatment
result differ in relief in pain intensity from each other and
from those who do not continue treatment?
Methods
Design
We performed a prospective, randomised and controlled trial
comparing TENS and sham TENS. A concealed block-wise ran-
domisation procedure was used, and patients, therapists and
research assistants were blinded for treatment allocation.
Subjects
Patients with chronic pain participating in this study were
referred to the Pain Centre of the Radboud University Medical
Centre Nijmegen by their family doctor (approximately 30%) or
by a medical specialist (approximately 70%). Anaesthesiologists
and physiotherapists of the Pain Centre screened patients for
TENS treatment.
Patients were eligible for this study if they met the inclusion
criteria. Inclusion criteria were: (1) patients with chronic pain of
benign origin referred to the Pain Centre, (2) duration of pain >6
months, (3) age above 18 years. Exclusion criteria were: (1) pre-
vious TENS treatment (because this could affect sham TENS
credibility [13]), (2) pain in face or head (because visible elec-
trode placement might affect compliance, and hair could impair
optimal electrode placement), (3) several different pain sites
(because of the limited area TENS electrodes can serve), (4) his-
tory of a cerebral vascular accident (because possible spinothal-
amocortical pathway damage could affect the outcome of TENS
– and possibly sham TENS treatment, too), (5) no
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relatives/friends to help replace electrodes, thus jeopardising
optimal TENS use), (6) involvement in ongoing litigation
because of their pain [11] and (7) psychological intervention
proposed by the Pain Centre psychologists (this would interact
with TENS treatment outcome in an unpredictable way, and
withholding it would be unethical). Eligible patients were
included in this study after signing informed consent. The
Central Committee on Research Involving Human Subjects
approved this study.
Apparatus
For TENS and sham TENS treatment, identical devices (ELPHA
II 1000, Danmeter A/S, Denmark) were used, which were spe-
cially prepared for this study. On the devices’ display, the current
intensity level was visible with a warning indicator for low bat-
tery load. Stimulation pulse frequency was set to 80 Hz and
pulse width to 50 µs for both channels (high-frequency TENS).
Pulses were delivered with an asymmetrical biphasic waveform
in a continuous pattern. Maximum output was 40 mA constant
current at a minimum of 2.0 kOhm electrode resistance. Sham
TENS devices showed a maximum of 10 or 20 mA on the dis-
play, but no current was actually delivered to the electrodes.
Duration of actual use of the device (referred to as “compli-
ance”) was registered and could be read out by pressing a special
key combination. Patients were not aware of this feature.
Disposable 5x6.4 cm self-adhering electrodes were used with an
active area of 6.5 cm2.
General procedure
Patients eligible for the TENS treatment received written infor-
mation in which they were asked to participate in the study. In
the letter, it was explained that TENS seems to be effective at
high and low intensities, and that treatment would be by one of
these two options. There would also be a chance of receiving a
sham TENS device in which the settings of pulses were neither
effective nor harmful.
After inclusion, baseline measures were carried out and
details of the TENS treatment procedure were explained.
Patients were told that “chronic pain is due to changes in the
central nerve system which function as an amplifier for pain
stimuli, and that TENS would serve as an inhibitory control but-
ton for this amplifier by using specific mild stimulation”. For
seven days before planned start of treatment, patients had to fill
in a VAS for pain at the same time every day, starting on Friday.
The next Friday – when treatment was started – the patient
visited the physiotherapist for electrode application and for
instruction on both TENS treatment modalities. Electrodes were
applied over the superficial cutaneous nerves in the painful seg-
ment(s), determined by the physiotherapist, who also showed
how to replace them accurately if necessary [14]. Next the phys-
iotherapist let the patient experience the tingling (not pricking)
sensation accompanying “high intensity” TENS. Stimulation
intensity was then decreased to determine the level at which the
patient did not experience any sensation. This was explained to
be “low intensity” TENS. This intensity was adjusted to 10 or
20 mA by the physiotherapist (but not visible for the patient) if
necessary, and the setting shown to the patient to make the
patient believe that at 10 or 20 mA he or she would not experi-
ence any sensation.
Once acquainted with the method of treatment, the patient
left the room and visited the research assistant whose only task
was to deliver the high frequency or sham TENS device to the
patient, as determined by the randomisation list. With a written
instruction how to use the device and not to change pain med-
ication the patient left the outpatient clinic. Ten days later, the
patient returned for evaluation of the treatment effect. Before
visiting the researcher, the receptionist asked the patient to leave
the “TENS” device with her, “to check it for proper function”.
The reason was twofold: the receptionist could register the
TENS use, and the researcher would not have access to the
TENS device.
Outcome measures
The primary outcome was the proportion of patients satisfied
with the initial treatment result and willing to continue treatment
(yes or no).
The secondary outcome measure was pain intensity. Pain
intensity was measured using a 10-cm VAS, ranging from no pain
at all to the most intense pain imaginable [15]. Patients were
instructed to rate their pain from that particular moment at the
same time every day for a period of 14 days, starting one week
before treatment. Multiple measures of pain intensity across time
maximise the reliability and validity of pain assessment [16].
Compliance and placebo credibility
Duration of TENS use served as a measure for compliance. Data
collection for TENS use was performed by the receptionist while
the patient visited the researcher for treatment evaluation.
During evaluation of short-term effects, patients were asked
how certain they felt about having a TENS or sham device using
a questionnaire according to Deyo et al. [13].
Sample size
Two main evaluations were planned for this study: a short-term
evaluation after ten days of treatment and a long-term evaluation
after one year of treatment. The number of patients in each treat-
ment group was based on long-term outcome. Assuming that
35% of the patients in the TENS group and 15% in the sham
TENS group would be successfully treated after one year, then
72 patients per group would be needed to show this difference
for a power of 80% and a two-sided alpha value of p=0.05 (chi
square test). Allowing for dropouts, this suggested the inclusion
of about 80 patients per group.
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Statistical methods
All analyses were based on the intention-to-treat population,
defined as all randomised patients that started with treatment.
The level of significance used was 0.05. The primary outcome
parameter was the proportion of patients willing to continue
(sham) TENS (yes or no). The difference between the two
treatment groups was tested with the chi square test. The sec-
ond outcome parameter was the difference in the time course
of the VAS score during the first treatment week and the mean
of the VAS score in the baseline week. These were analysed
using a mixed repeated measures model, including as fixed
factors time (day), treatment (TENS and sham TENS) and all
their first-order interactions, and furthermore a random inter-
cept per patient. In addition, we performed secondary, post
hoc testing for the differences in VAS time courses between
patients continuing and not continuing treatment in the two
treatment groups using a mixed repeated measures model,
including the fixed factors treatment (TENS and sham TENS)
and result of treatment (continuing treatment or not), the
repeated measures factor time (day) and all their first-order
interactions, and furthermore a random intercept per patient.
Differences in compliance were analysed using Wilcoxon’s
two-sample test. The relationship between patients’ opinion
about device type and real TENS or sham TENS use was
analysed using a chi square test. For the strength of the asso-
ciations, the phi coefficient was calculated. Phi is interpreted
as a Pearson’s r and phi squared is the proportion of the total




From January 2000 until January 2003, 406 consecutive
patients were proposed for TENS treatment. Two hundred
and three patients were excluded. One hundred and sixty-
five patients signed informed consent. Two of the included
patients withdrew before the actual treatment took place;
they were both assigned to the TENS group. Therefore, 163
patients entered this study (for details see Fig. 1).
The main pain diagnoses were: nerve injury, compres-
sion or surgery and diabetic neuropathy (n=17); dorsal
root injury, compression or surgery (n=24); articular
degeneration and osteoporosis of the spine (n=47); articu-
lar degeneration of hip, knee or ankle (n=5); unclassified
limb or back pain (n=10); bursitis and tendonitis (n=12);
postfracture or postsurgery pain (n=33); visceral pain
(n=7); and whiplash injury (n=8).
Demographic data and pain characteristics were simi-
lar for the TENS and sham TENS groups (Tables 1 and 2).
The baseline week’s time course for pain VAS values did
not differ between the TENS and sham TENS groups.
Baseline VAS time course was also similar for patients
willing to continue treatment or not (see Fig. 2).
Outcome
The proportion of patients willing to continue treatment dif-
fered significantly (x2=3.8, p=0.05) for TENS (58%) com-
pared to sham TENS (42.7%). Pain intensity was signifi-
cantly reduced for factor time (p<0.001), but not for treat-
ment modality (p=0.53) or interaction of time and treatment
modality (p=0.52) during the treatment week. With post hoc
testing, pain intensity for patients willing to continue treat-
ment differed significantly (in time and magnitude;
p<0.001) from patients not willing to continue treatment,
only for the treatment week. Mean proportion of relief in
pain intensity for patients willing to continue treatment was
28.5% (SEM=3.9%), 27.0% (SEM=5.0) for the TENS group
and 30.6% (SEM=6.5) for the sham TENS group. Pain
intensity increased by 1% (SEM=8.0) in the TENS group
and 10% (SEM=5.0) in the sham TENS group, for patients
not willing to continue treatment. There were, however,
again no differences according to treatment modality. The
time course of pain intensities is illustrated in Figure 2.
Compliance and placebo credibility
Compliance data were missing in two patients, both in the
TENS group; from one because of a device handling mis-
take during retrieval of the data, and from another due to
technical TENS device failure. There was no significant
difference in compliance, measured via duration of device
operation, between the TENS and sham TENS groups
(p=0.89). However, in patients not willing to continue
treatment, the sham TENS group used the device for
slightly longer than the TENS group (p=0.04; see Table 3).
We found a significant relationship between patients’
opinion about having a sham or real TENS device and
actually having a sham or real TENS device (x2=13.2,
p<0.001, phi=0.28).
Discussion
The proportion of patients satisfied with treatment results
and willing to continue treatment was greater in the TENS
group compared to the sham TENS group. However, we
found no difference in pain intensity over time between
patients receiving TENS or sham TENS. Pain intensity
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Fig. 1 Trial profile
Table 1 Baseline demographic details
TENS (n=81) Sham TENS (n=82) Total (n=163)
Age
Mean±SE (years) 48.4±1.6 51.6±1.4 50.2±1.1
Gender, n (%)
Male 33 (41) 33 (40) 66 (40)
Female 48 (69) 49 (60) 97 (60)
Nationality, n (%)
Dutch 79 (98) 81 (99) 160 (98)
Others 2 (2) 1 (1) 3 (2)
Civil state, n (%)
Single 10 (12) 5 (6) 15 (9)
Married/partner 67 (83) 71 (87) 138 (85)
Divorced 1 (1) 4 (5) 5 (3)
Widow(er) 3 (4) 2 (3) 5 (3)
Education, n (%)
Elementary school 13 (16) 15 (18) 28 (17)
Secondary education 54 (67) 59 (72) 113 (69)
Higher education 12 (15) 8 (10) 20 (13)
University 2 (2) 0 (0) 2 (1)
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equally decreased during both treatment applications, only
for patients satisfied with treatment result and willing to con-
tinue treatment. For patients not willing to continue treat-
ment, pain intensities did not differ from baseline values. As
shown in Figure 2, the results of real/sham TENS appeared
to be initiated right from the start of treatment and to
increase with time, during repeated treatment applications.
Comparison of our results with those of other TENS stud-
ies in chronic pain
In our study 58% of the patients were willing to continue
TENS after an initial short trial period, which is in accord
Table 2 Baseline pain characteristics
TENS (n=81) Sham TENS (n=82) Total (n=163)
Intensity of pain (VAS, 0–100 mm)
Mean±SE 62.2±2.1 61.5±2.0 61.9±1.4
Duration of pain (years)
Mean±SE 6.2±0.8 6.6±0.9 6.4±0.6
Median (range) 3.6 (0.6–42.1) 4.1 (0.2–58.7) 3.7 (0.2–58.7)
Variation of pain during the day, n (%)
Almost constant pain
Constant, not changing 29 (36) 18 (22) 47 (29)
Constant, increasing during the day 30 (37) 39 (48) 69 (42)
Constant, decreasing during the day 1 (1) 1 (1) 2 (1)
Variable pain
Variable pain, no pain free moments 16 (20) 18 (22) 34 (21)
Variable pain, with pain free moments 5 (6) 4 (4) 9 (5)
Other 0 (0) 2 (2) 2 (1)
Origin of pain, n (%)
Accident 23 (28) 18 (22) 41 (25)
Surgery 19 (23) 22 (27) 41 (25)
Disease 6 (7) 11 (13) 17 (10)
Injury 5 (6) 4 (5) 9 (6)
Long period of overstraining oneself 9 (11) 14 (17) 23 (14)
Other 2 (2) 0 (0) 2 (1)
Not known by patient 17 (21) 13 (16) 30 (18)
Pain course, n (%)
Gradually 25 (31) 30 (37) 55 (34)
Sudden onset 56 (69) 52 (63) 108 (66)
Recurrent pain, n (%)
Yes, I had these complaints before 38 (47) 38 (47) 76 (47)
No, this was the first time 43 (53) 43 (52) 86 (52)
Fig. 2 Time course of VAS scores (mean±SEM) for satisfied patients
(+) and non-satisfied patients (–) of the TENS and sham TENS
group, during baseline (day 1–7) and treatment periods (day 8–14)
Table 3 Compliance; (sham) TENS use in hours per day
Treatment Satisfied? n Missing Mean (SD)
Sham TENS No 47 0 11.6* (4.9)
TENS No 33 1 9.8* (2.7)
Sham TENS Yes 35 0 11.0* (3.7)
TENS Yes 46 1 11.5* (4.4)
*p=0.04 for difference in compliance between sham TENS and
TENS group for patients not satisfied with treatment result
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with the results of Köke et al. [17], who found 56% of the
patients willing to continue TENS treatment after a trial
period of two weeks.
For those patients willing to continue treatment, pain
intensity decreased, on average, equally for TENS and
sham TENS, by 28.5% compared to baseline, which is
comparable to the results of Köke et al. [17], who found
for patients with a positive assessment an average 33.5%
pain reduction after two weeks of TENS treatment. Other
reported relative differences in percentage change in pain
severity from baseline ranged from 11% to 38% [18]. For
the TENS treatment group as a whole, we found an aver-
age pain reduction of 16%, which falls within this range.
Perhaps more important is the fact that our findings
clearly show that TENS significantly decreased pain
intensity ratings in a cumulative manner over repeated
treatment sessions, in contrast to animal research, where
repeated TENS administration results in gradual diminu-
tion of analgesic effect via opioid tolerance [19], but
(except for the sham TENS) in line with the results of
Marchand et al. [10]. However, how much the pain
results will improve when extending the treatment period
needs to be investigated. These findings may provide an
explanation for the inconclusive results for TENS in
chronic pain [1], as duration and frequency of TENS
stimulation sessions vary largely between studies and, in
general, stimulation periods were short and frequency of
application was low [2]. Osiri et al. [20] found, as a result
of reviewing TENS studies in osteoarthritis, that a signif-
icant difference in pain relief was achieved in studies
with an intervention period of TENS application of at
least 4 weeks.
In our study we applied high-frequency TENS with a
frequency of 80 Hz, a short pulse width of 50 µs and low-
intensity stimulation to selectively stimulate A-beta affer-
ent neurons in the segment(s) of pain. This was assured by
making the patient experience the different sensations of
tingling (A-beta fibres) and pricking (nociceptive A-fibres)
[21]. Patients used their device on average from 9.8 to 11.6
h/day, which is common in the treatment of chronic pain
[3, 22]. Whether different application parameters for
TENS would have improved our results is questionable.
Köke et al. [17] used high-frequency TENS comparable
with our TENS application and found no difference in
results of either high- or low-intensity stimulation. Nash et
al. [23] compared continuous and pulsed high- and low-
frequency TENS at multiple intensity levels with a maxi-
mum just tolerated by the patients; they found however no
differences in effect for the different TENS applications. In
both studies, like in our study, patients were treated for
various pain conditions. Recently, Defrin et al. [24] found
noxious high-frequency stimulation to be more effective
than innocuous stimulation in patients with osteoarthritis.
However, they used a non-portable device with a stimula-
tion frequency of 4000 Hz, which makes it less compara-
ble with the standard TENS application.
Differences regarding outcomes
Our results suggest that pain intensity measured by VAS
versus asking the patient’s opinion about treatment result
represent different, albeit related, pain outcome endpoints.
As we found no differences in pain improvement by VAS
scores between the TENS and sham TENS group, it would
seem that patients’ opinions about treatment results reflect
the additional integration of factors apart from pain in
assessing the clinical success of treatment. However it
should be noted that VAS scores for pain intensity were
measured once a day at a fixed time, reflecting the pain
intensity at that particular moment, whereas patients’
opinions about treatment result should include all
improvements experienced by the patient during the
whole treatment period. Interestingly, for patients satis-
fied with treatment results and willing to continue treat-
ment, the mean pain reduction was 28.5%, a clinically
important difference [25], whereas for patients not willing
to continue treatment there was no improvement in pain
intensity during the treatment period as compared to the
baseline period. Regarding the accuracy of pain integra-
tion into this assessment, it is interesting to note that
Coghill et al. [26] found that individuals with similar acti-
vation patterns of the somatosensory, the anterior cingu-
late and prefrontal cortex provided similar subjective
reports of pain magnitude. Finally, our findings seem to
support the theory that patients either do or do not respond
to TENS and sham TENS.
Specific versus non-specific effects of TENS treatment
Our results show that, for patients willing to continue
treatment, there is no difference in relief in pain intensi-
ty between TENS and sham TENS, suggesting the same
working mechanism, possibly a placebo response.
Placebo effects can be very impressive; Evans found
placebo to be as effective as a standard dose of mor-
phine in 56% of subjects [27]. Placebo response in
TENS treatment has been said to range from less than
40% to more than 60% [28]. However, Vase et al. [29],
studying chronic irritable bowel syndrome patients,
found that the addition of a verbal suggestion for pain
relief could increase the magnitude of placebo analgesia
to that of an active agent. Therefore, it cannot be exclud-
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ed that the similar pain reductions achieved in the two
groups are accomplished by different mechanisms. In
this case it is interesting to know that in animal research
high-frequency TENS decreased central sensitisation
induced by inflammation in spinal dorsal horn neurons
by activating delta-opioid receptors (for review see
[30]), and in contrast, the placebo response in man is
accomplished by the activation of mu-opioid receptors
[7, 31]. However, further research in the underlying
working mechanisms of TENS compared to sham TENS
in man seems warranted.
Placebo credibility
The credibility of sham TENS has been challenged
because patients do not feel the typical buzzing sensation
of high-frequency TENS [1, 2]. In the present study,
patients’ belief regarding real versus sham TENS was
related to the actual use of real or sham TENS. However,
we believe that the present results do provide support for
the credibility of our version of sham TENS. Firstly, the
strength of the relation was weak (phi=0.28; resulting in
a shared variance of approximately 8%). Secondly, there
was no difference in actual use (compliance) between the
real and sham TENS devices – and this device use was
registered without the knowledge of the patient.
Furthermore, subgroup analysis demonstrates that, on
average, patients not willing to continue treatment as a
whole used their TENS device approximately 1 h 45 min-
utes less per day than sham TENS users. We would there-
fore suggest that our patients treated sham TENS as a
credible treatment modality.
Critique of study design
The strong point of the present study is that we have suc-
ceeded in completing a large prospective, randomised,
controlled and double-blind clinical trial of TENS treat-
ment for chronic pain. In particular, a concerted effort
was made to ensure that the sham TENS used was credi-
ble, and that the blinding of patients, therapists and
researchers was maintained throughout the study. The
fact that we did not include a natural history group might
be considered a weak point, because pain improvement
during treatment could have been attributed to the natur-
al course of the pain. However, patients referred to the
Pain Centre had to wait for three months before being
seen, during which time their pain remained stable.
Furthermore, pain reduction started promptly with the
beginning of treatment (see Figure 2). It should be noted
that adding a third natural history group to the study
design would have reduced the probability of benefit for
the volunteers. Thus patients would have entered the
study with low expectations, violating the external valid-
ity of the study [32].
Our choice of the outcome measures may be consid-
ered a weak point, as they do not fully reflect all dimen-
sions of chronic pain as proposed by the IMMPACT rec-
ommendations [33]. However, after this short treatment
period we did not expect to achieve clinically relevant
changes in disabilities. In this respect it is of importance
to mention that Fishbain et al. [22] found that patients
with chronic pain, who continued to use TENS after a
trial period, improved by less pain interference with
work, home and social activities, and increased activity
level and pain management, after more than 6 months of
TENS treatment. Whether these long-term results of
TENS treatment differ from sham TENS still needs to be
investigated.
Finally, the results of this study imply that those
patients that experience relief by daily TENS (or sham
TENS) application, expressed by willingness to continue
treatment, improve by means of a significant pain reduc-
tion and that this amount of pain reduction is dependent
on the period of stimulation. These results may have
important implications for future TENS studies and clini-
cal application, when defining response to treatment by
means of a percentage change of pain intensity.
Conclusions
After ten days of TENS or sham TENS application, the
proportions of patients satisfied with treatment results and
willing to continue treatment differed significantly in
favour of TENS. However, no differences in pain intensi-
ty were found for patients treated with TENS or sham
TENS. Only for patients satisfied with treatment result,
pain intensity gradually decreased equally both for TENS
and sham TENS with repeated treatment application. In
conclusion, we found that the efficacy of short-term
TENS treatment depends on the choice of outcome mea-
sure and the period of stimulation.
Further research is needed to explore the mechanisms
underlying the effects of TENS versus sham TENS in man.
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